

In re Application of: Joseph ITSKOVITZ-ELDOR et al
Serial No.: 10/536,734
Filed: May 27, 2005
Office Action Mailing Date: February 17, 2010

Examiner: Kim, Taeyoon
Group Art Unit: 1651
Attorney Docket: 29601
Confirmation No.: 3958

In the Claims:

1-192. (Cancelled)

193. (Previously Presented) A method of generating cells capable of secreting insulin, the method comprising:

(a) subjecting mammalian embryonic stem cells to a first set of culturing conditions selected suitable for inducing formation of embryoid bodies including cells displaying at least one characteristic associated with a pancreatic islet cell progenitor phenotype;

(b) dissociating said embryoid bodies into single cells displaying at least one characteristic associated with a pancreatic islet phenotype;

(c) subjecting said cells displaying at least one characteristic associated with a pancreatic islet cell progenitor phenotype to a second set of culturing conditions selected suitable for formation of surface bound cell clusters including insulin producing cells and inhibiting growth of non insulin producing cells, thereby generating cells capable of secreting insulin

(d) dissociating said surface bound cell clusters into single cells and culturing said single cells under non-adherent conditions to thereby form suspended cell clusters, said suspended clusters being enriched with cells capable of secreting insulin as compared to said surface bound cell clusters; and

(e) isolating said suspended clusters.

194. (Withdrawn) A method of producing insulin, the method comprising:

(a) subjecting mammalian embryonic stem cells to a first set of culturing conditions selected suitable for differentiation of at least a portion of said mammalian embryonic stem cells into cells displaying at least one

In re Application of: Joseph ITSKOVITZ-ELDOR et al
Serial No.: 10/536,734
Filed: May 27, 2005
Office Action Mailing Date: February 17, 2010

Examiner: Kim, Taeyoon
Group Art Unit: 1651
Attorney Docket: 29601
Confirmation No.: 3958

characteristic associated with a pancreatic islet cell progenitor phenotype; and

- (b) subjecting said cells displaying at least one characteristic associated with a pancreatic islet cell progenitor phenotype to a second set of culturing conditions selected suitable for formation of surface bound cell clusters including insulin producing cells, thereby producing the insulin.

195-196 (Cancelled)

197. (Previously Presented) The method of claim 193, further comprising:

- (f) isolating the cells capable of secreting insulin.

198. (Cancelled)

199. (Previously Presented) The method of claim 193, wherein said suspended cell clusters are characterized by a proportion of the cells capable of secreting insulin of at least 4 percent.

200. (Previously Presented) The method of claim 193, wherein an insulin secretion rate capacity of the cells capable of secreting insulin. of said suspended cell clusters is at least 6 microunits insulin per one hundred thousand cells per hour when subjected to conditions suitable for inducing insulin secretion.

201. (Withdrawn) The method of claim 194, further comprising:

- (c) harvesting the insulin..

202-204. (Cancelled)

In re Application of: Joseph ITSKOVITZ-ELDOR et al
Serial No.: 10/536,734
Filed: May 27, 2005
Office Action Mailing Date: February 17, 2010

Examiner: Kim, Taeyoon
Group Art Unit: 1651
Attorney Docket: 29601
Confirmation No.: 3958

205. (Previously Presented) The method of claim 193, wherein said dissociating said surface bound cell clusters into single cells is effected by trypsinization of said surface bound cell clusters.

206-213. (Cancelled)

214. (Previously Presented) The method of claim 193, wherein said mammalian embryonic stem cells are human embryonic stem cells.

215. (Previously Presented) The method of claim 214, wherein said human embryonic stem cells are selected from the group consisting of I6 cells, H9 cell derived cells, and H13 cells.

216. (Withdrawn) The method of claim 215, wherein said H9 cell derived cells are H9.2 cells.

217. (Withdrawn) An insulin producing cell cluster comprising insulin producing cells being maintainable in culture for at least 14 days, wherein a proportion of said insulin producing cells in the cell cluster is at least 4 percent.

218. (Withdrawn) The insulin producing cell cluster of claim 217, wherein said proportion of said insulin producing cells in the cell cluster is at least 32 percent.

219. (Withdrawn) The insulin producing cell cluster of claim 217, wherein an insulin secretion rate capacity of said insulin producing cells is at least 6 microunits insulin per one hundred thousand cells per hour.

In re Application of: Joseph ITSKOVITZ-ELDOR et al
Serial No.: 10/536,734
Filed: May 27, 2005
Office Action Mailing Date: February 17, 2010

Examiner: Kim, Taeyoon
Group Art Unit: 1651
Attorney Docket: 29601
Confirmation No.: 3958

220. (Withdrawn) The insulin producing cell cluster of claim 217, wherein the cell cluster further comprises cells displaying at least one characteristic associated with a pancreatic islet cell phenotype selected from the group consisting of an endocrine cell precursor phenotype, an alpha cell phenotype, a beta cell phenotype, a delta cell phenotype, and a neuronal cell phenotype

221. (Withdrawn) The insulin producing cell cluster of claim 217, wherein said insulin producing cell cluster produces human insulin.

222. (Withdrawn) The insulin producing cell cluster of claim 217, wherein said insulin producing cell cluster includes human cells.

223. (Withdrawn) The insulin producing cell cluster of claim 222, wherein said human cells have a genotype of I6 cells, H9 cell derived cells, and H13 cells.

224. (Withdrawn) The insulin producing cell cluster of claim 223, wherein said H9 cell derived cells are H9.2 cells.

225. (Withdrawn) A method of treating a pancreatic disease in a subject, the method comprising:

- (a) subjecting mammalian embryonic stem cells to a first set of culturing conditions selected suitable for differentiation of at least a portion of said mammalian embryonic stem cells into cells displaying at least one characteristic associated with a pancreatic islet cell progenitor phenotype;
- (b) subjecting said cells displaying at least one characteristic associated with a pancreatic islet cell progenitor phenotype to a second set of

In re Application of: Joseph ITSKOVITZ-ELDOR et al
Serial No.: 10/536,734
Filed: May 27, 2005
Office Action Mailing Date: February 17, 2010

Examiner: Kim, Taeyoon
Group Art Unit: 1651
Attorney Docket: 29601
Confirmation No.: 3958

culturing conditions selected suitable for formation of surface bound cell clusters including insulin producing cells; and

- (c) administering a therapeutically effective dose of said insulin producing cells to the subject, thereby treating the pancreatic disease.

226. (Withdrawn) The method of claim 225, further comprising isolating said surface bound cell clusters and optionally said insulin producing cells therefrom prior to step (c).

227. (Withdrawn) The method of claim 225, further comprising:

- (d) dissociating said surface bound cell clusters into single cells including said insulin producing cells; and
- (e) subjecting said single cells to a third set of culturing conditions selected suitable for maintaining said insulin producing cells in culture for at least 14 days prior to step (c).

228. (Withdrawn) The method of claim 225, wherein a total insulin secretion capacity of said insulin producing cells of said suspended cell clusters is at least 0.50 microunits insulin per one hundred thousand cells.

229. (Withdrawn) The method of claim 225, wherein said mammalian embryonic stem cells are human embryonic stem cells.

230. (Withdrawn) The method of claim 229, wherein said human embryonic stem cells are selected from the group consisting of I6 cells, H9 cell derived cells, and H13 cells.

In re Application of: Joseph ITSKOVITZ-ELDOR et al
Serial No.: 10/536,734
Filed: May 27, 2005
Office Action Mailing Date: February 17, 2010

Examiner: Kim, Taeyoon
Group Art Unit: 1651
Attorney Docket: 29601
Confirmation No.: 3958

231. (Withdrawn) The method of claim 230, wherein said H9 cell derived cells are H9.2 cells.

232. (Withdrawn) The method of claim 225, wherein said insulin producing cells are syngeneic with or allogeneic with the subject.

233. (Withdrawn) The method of claim 225, wherein the subject is a human or a non human mammal.

234. (Withdrawn) The method of claim 225, wherein said administering is effected by transplantation or injection of said insulin producing cells into the pancreas of the subject.